“Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-Week Phase 3b ADHAND Trial”. 2026. SKIN The Journal of Cutaneous Medicine 10 (2): s744. https://doi.org/10.25251/ppt8ep84.